Scientists Find Protein That May Help Control Prostate
Cancer
(HealthDay): "HealthDay - FRIDAY, Dec. 3 (HealthDay News) -- A protein that regulates
prostate stem cell self-renewal and also plays a role in the
transformation of healthy cells into prostate cancer cells has been
identified by U.S. scientists."
The findings could prove important in efforts to one day find ways to control cancer growth and progression.
Saturday, December 4, 2010
Testosterone boost does not last
Testosterone boost no lasting help : "NEW YORK (Reuters Health) - Testosterone gels may offer frail, old men a chance to regain some of their youthful vigor, but the effects fade away as soon as they stop treatment, British researchers report.
Testosterone is not approved for treating frailty, but a handful of studies suggest short-term treatment increases muscle mass, strength and quality of life in older men.
Other work has hinted that treating middle-aged and older men with the hormone might increase their risk of heart disease and prostate problems, however, making short treatments all the more attractive.
But the idea that a brief treatment would provide long-term benefits appears to be wishful thinking.
"
Testosterone is not approved for treating frailty, but a handful of studies suggest short-term treatment increases muscle mass, strength and quality of life in older men.
Other work has hinted that treating middle-aged and older men with the hormone might increase their risk of heart disease and prostate problems, however, making short treatments all the more attractive.
But the idea that a brief treatment would provide long-term benefits appears to be wishful thinking.
Friday, December 3, 2010
FDA Panel Votes Against Drugs Said to Prevent Prostate Cancer (HealthDay)
FDA Panel Votes Against Drugs Said to Prevent Prostate
Cancer
(HealthDay): "HealthDay - WEDNESDAY, Dec. 1 (HealthDay News) -- A U.S. Food and Drug
Administration advisory committee on Wednesday voted against approving
two drugs for the prevention of prostate cancer, the third-highest cancer
killer of men."
The panel voted 17-0, with one abstention, that the risks of Merck's Proscar outweighed its benefits, according to the Associated Press. And in a similar vote, the panel voted 14-2, with two abstentions, against GlaxoSmithKline's Avodart. Both drugs are already approved to treat enlarged prostates.
Cancer
(HealthDay): "HealthDay - WEDNESDAY, Dec. 1 (HealthDay News) -- A U.S. Food and Drug
Administration advisory committee on Wednesday voted against approving
two drugs for the prevention of prostate cancer, the third-highest cancer
killer of men."
The panel voted 17-0, with one abstention, that the risks of Merck's Proscar outweighed its benefits, according to the Associated Press. And in a similar vote, the panel voted 14-2, with two abstentions, against GlaxoSmithKline's Avodart. Both drugs are already approved to treat enlarged prostates.
Wednesday, December 1, 2010
Watching and waiting may be best for prostate cancer
Watching and waiting may be best option for prostate cancer: "CHICAGO (Reuters) - Because most men have at least one side effect from treatment, older men with low-risk prostate cancer may be better off getting regular check-ups that rushing to get surgery or radiation, researchers using a computer model suggested on Tuesday.
Active surveillance was associated with the highest benefit in terms of quality adjusted life expectancy (by at least 6 additional months) compared with other treatment options
"
Active surveillance was associated with the highest benefit in terms of quality adjusted life expectancy (by at least 6 additional months) compared with other treatment options
Study links finger length to prostate cancer risk
Prostate cancer risk linked to finger length: "LONDON (Reuters) - Men with long index fingers have a lower risk of prostate cancer, British scientists said on Wednesday, a finding that could be used to help select those who need regular screening for the disease.
Men whose index finger is longer than their ring finger were one-third less likely to develop the disease than men with the opposite pattern of finger lengths.
"
Men whose index finger is longer than their ring finger were one-third less likely to develop the disease than men with the opposite pattern of finger lengths.
Tuesday, November 30, 2010
Issues seen with drugs to curb prostate cancer: FDA
FDA is concerned about new uses of existing prostate drugs: "WASHINGTON (Reuters) - U.S. regulatory staff have raised concerns about data for two drugs by GlaxoSmithKline Plc and Merck & Co Inc and their effect on reducing the risk of prostate cancer in certain men.
Both drugs are already approved to treat symptoms in men with enlarged prostate
Food and Drug Administration staff, in documents released ahead of a public advisory meeting on Wednesday, said overall, large trials for each of the drugs showed benefits after four years with Avodart and seven years with Merck's drug, Proscar -- mostly in men with certain grades of the cancer.
They noted that "neither trial was adequately designed and conducted to characterize the ultimate outcomes of interest," such as death. "In both trials, there was also an unexpected finding of an increased incidence of high-risk prostate cancers among men receiving" the drugs
"
Both drugs are already approved to treat symptoms in men with enlarged prostate
Food and Drug Administration staff, in documents released ahead of a public advisory meeting on Wednesday, said overall, large trials for each of the drugs showed benefits after four years with Avodart and seven years with Merck's drug, Proscar -- mostly in men with certain grades of the cancer.
They noted that "neither trial was adequately designed and conducted to characterize the ultimate outcomes of interest," such as death. "In both trials, there was also an unexpected finding of an increased incidence of high-risk prostate cancers among men receiving" the drugs
Subscribe to:
Posts (Atom)